Search - tctmd.com

Displaying 1 - 20 of 121

Sort: Relevancy | Date

What Makes MedTech Great—or Not—and Envisioning Its Future

News Conference News TCT 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

November 04, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

Presentation TCT 2025

Transcatheter Treatment of Chronic Aortic Regurgitation Using the Novel J-Valve System: 6-Months Results from a Transfemoral Early Feasibility Study (Edwards Lifesciences)

Presenter: Santiago Garcia

October 27, 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

News Conference News TCT 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

October 25, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

October 30, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

News Conference News TCT 2023

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

November 03, 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

News Conference News TCT 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

Yael L. Maxwell

October 30, 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.